Forty-eight hirsute women were treated with spironolactone 100 mg twice daily for 3 to 12 months. Both facial and body hirsuties improved by 30–40%, and there was a threefold reduction in frequency of local treatments such as waxing or shaving. Plasma testosterone fell by 30%, though the improvement in hirsuties grading did not correlate with the fall in plasma testosterone. Six subjects discontinued treatment because of lack of effect, and 4 because of menstrual disturbance. Spironolactone was equally effective in the treatment of idiopathic hirsutism and of the polycystic ovary syndrome.
ConeyPJ. Polcystic ovarian disease: Current concepts of pathophysiology and therapy. Fertil Steril1984; 42: 667–82
2.
LoriauxDLMenardRTaylorAPitaJCSantenR. Spironolactone and endocrine dysfunction. Ann Intern Med1976; 85: 630–6
3.
OberKPHennessyJF. Spironolactone therapy for hirsutism in a hyperandrogenic woman. Ann Intern Med1978; 89: 643–4
4.
BoisselleATremblayRR. New therapeutic approach to the hirsute patient. Fertil Steril1979; 32: 276–9
5.
ShapiroGEvronS. A novel use of spironolactone: Treatment of hirsutism. J Clin Endocrinol Metab1980; 51: 429–32
6.
CummingDCYangJCRebarRWYenSSC. Treatment of hirsutism with spironolactone. JAMA1982; 247: 1295–8
7.
MilewiczASilberDKirschnerMA. Therapeutic effects of spironolactone in polycystic ovary syndrome. Obstet Gynecol1983; 61: 429–32
8.
MessinaMManieriCBiffignandiPMassucchettiCNoviRFMolinattiGM. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. J Endocrinol Invest1983; 6: 23–7
9.
AbramoviciYGuilletFMatteRChaiebLBelangerR. Spironolactone in idiopathic hirsutism. Clinical and biological evaluations of treatment. Annales d'Endocrinologie (Paris)1983; 44: 393–6
10.
SpandriPGangemiMNardelliGB, Testosterone, 17 KS, 17B2, FSH-LH variations and hirsutism modifications during spironolactone therapy. Clin Exp Obst Gyn1984; 11: 49–54
11.
LoboRAShoupeDSerafiniPBrintonDHortonR. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril1985; 43: 200–5
12.
Dorrington-WardPMcCartneyACEHollandS, The effect of spironolactone on hirsutism and female androgen metabolism. Clin Endocrinol1985; 23: 161–7
13.
GreenblattDJKoch-WeserJ. Adverse reactions to spironolactone: A report from the Boston Collaborative Drug Surveillance Program. JAMA1973; 225: 40–3
14.
BoiselleADioneFTTremblayRR. Interaction of spironolactone with rat skin androgen receptor. Can J Biochem1979; 57: 1042–6
15.
EilCEkelsonSK. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J Clin Endocrinol Metab1984; 59: 51–5
16.
MenardRHStrippBGilletteJR. Spironolactone and testicular cytochrome P-450: Decreased testosterone formation and in several species and changes in hepatic drug metabolism. Endocrinology1974; 94: 1628–36
